About Tobira Development (NASDAQ:TBRA)
Tobira Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases. The Company's product candidate, cenicriviroc (CVC), is a first-in-class immunomodulator and dual inhibitor of C-C chemokine receptor type 2 (CCR2) and C-C chemokine receptor type 5 (CCR5) in late stage development for the treatment of NASH, a serious liver disease that can progress to cirrhosis, liver cancer and liver failure. CVC is also being investigated to address primary sclerosing cholangitis (PSC), a disease which causes inflammation and scarring of the bile ducts, eventually leading to liver damage. The Company’s pipeline also includes evogliptin, a selective dipeptidyl peptidase 4 (DPP-4) inhibitor, which it plans to develop for NASH in combination with CVC.
Industry, Sector and Symbol
Industry Bio Therapeutic Drugs
Trailing P/E Ratio-29.2291666666667
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on EquityN/A
Return on Assets-153.93%
Tobira Development (NASDAQ:TBRA) Frequently Asked Questions
What is Tobira Development's stock symbol?
Tobira Development trades on the NASDAQ under the ticker symbol "TBRA."
How were Tobira Development's earnings last quarter?
Tobira Development Inc (NASDAQ:TBRA) announced its earnings results on Tuesday, August, 9th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.63) by $0.08. The biopharmaceutical company earned $1.06 million during the quarter, compared to the consensus estimate of $0.15 million. View Tobira Development's Earnings History.
Who are some of Tobira Development's key competitors?
Some companies that are related to Tobira Development include Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Medivation (MDVN), Bioverativ (BIVV), Kite Pharma (KITE), bluebird bio (BLUE), Juno Therapeutics (JUNO), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Beigene (BGNE), Shire-Nps Pharmaceuticals (NPSP), Agios Pharmaceuticals (AGIO), AveXis (AVXS), Sarepta Therapeutics (SRPT), Array BioPharma (ARRY), TESARO (TSRO) and GW Pharmaceuticals PLC- (GWPH).
How do I buy Tobira Development stock?
Shares of Tobira Development can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How can I contact Tobira Development?
Tobira Development's mailing address is 701 Gateway Blvd Ste 300, SOUTH SAN FRANCISCO, CA 94080-7412, United States. The biopharmaceutical company can be reached via phone at +1-650-7416625.
MarketBeat Community Rating for Tobira Development (TBRA)MarketBeat's community ratings are surveys of what our community members think about Tobira Development and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Tobira Development (NASDAQ:TBRA) Earnings History and Estimates Chart
Tobira Development (NASDAQ TBRA) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/9/2016||Q216||($0.63)||($0.71)||$0.15 million||$1.06 million||View||N/A|
Tobira Development (NASDAQ:TBRA) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Tobira Development (NASDAQ:TBRA)
No dividend announcements for this company have been tracked by MarketBeat.com
Tobira Development (NASDAQ TBRA) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 6.20%
Institutional Ownership Percentage: 62.42%
Tobira Development (NASDAQ TBRA) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|10/31/2016||Pentwater Capital Management L||Major Shareholder||Buy||15,000||$41.84||$627,600.00|| |
|10/18/2016||Pentwater Capital Management L||Major Shareholder||Buy||40,000||$40.06||$1,602,400.00|| |
|10/17/2016||Pentwater Capital Management L||Major Shareholder||Buy||31,700||$40.07||$1,270,219.00|| |
|10/4/2016||Pentwater Capital Management L||Major Shareholder||Buy||4,481||$39.83||$178,478.23|| |
|9/29/2016||Pentwater Capital Management L||Major Shareholder||Buy||15,519||$39.49||$612,845.31|| |
|9/26/2016||Pentwater Capital Management L||Major Shareholder||Buy||50,000||$39.00||$1,950,000.00|| |
|9/23/2016||Pentwater Capital Management L||Major Shareholder||Buy||100,000||$39.19||$3,919,000.00|| |
|9/22/2016||Pentwater Capital Management L||Major Shareholder||Buy||1,624,200||$39.04||$63,408,768.00|| |
|7/13/2016||A/S Novo||Major Shareholder||Sell||59,067||$12.02||$709,985.34||1,914,541|| |
|7/7/2016||A/S Novo||Major Shareholder||Sell||92,119||$12.20||$1,123,851.80||2,016,691|| |
|6/30/2016||A/S Novo||Major Shareholder||Sell||66,814||$13.04||$871,254.56||2,073,022|| |
|6/6/2016||A/S Novo||Major Shareholder||Sell||187,500||$10.37||$1,944,375.00||2,093,905|| |
|3/4/2016||A/S Novo||Major Shareholder||Sell||190,000||$6.80||$1,292,000.00||2,361,405|| |
|11/18/2015||A/S Novo||major shareholder||Sell||225,000||$9.79||$2,202,750.00||2,471,405|| |
|5/4/2015||A/S Novo||Major Shareholder||Buy||838,041||$10.62||$8,899,995.42|| |
|5/4/2015||Parters Vii L P Domain||Major Shareholder||Buy||277,777||$10.62||$2,949,991.74|| |
|4/16/2014||Robert Kierlin||major shareholder||Buy||575,000||$6.00||$3,450,000.00||4,284,955|| |
|2/5/2014||Robert Kierlin||major shareholder||Buy||400,000||$5.00||$2,000,000.00||3,700,955|| |
|8/27/2013||Raphael Wisniewski||Director||Buy||1,215,708||$4.00||$4,862,832.00|| |
|8/27/2013||Rmi Investments S.A.R.L.||Major Shareholder||Buy||3,866,529||$4.00||$15,466,116.00|| |
Tobira Development (NASDAQ TBRA) News Headlines
|Tobira Development (TBRA) vs. CymaBay Therapeutics (CBAY) Head to Head Survey|
www.americanbankingnews.com - February 16 at 7:58 AM
|ADMA Biologics (ADMA) versus Tobira Development (TBRA) Head-To-Head Contrast|
www.americanbankingnews.com - December 30 at 5:20 AM
|Financial Comparison: Rigel Pharmaceuticals (RIGL) versus Tobira Development (TBRA)|
www.americanbankingnews.com - November 25 at 5:12 PM
|Financial Contrast: Tobira Development (TBRA) vs. The Competition|
www.americanbankingnews.com - September 18 at 8:34 PM
|Sarepta Therapeutics (SRPT) and Tobira Development (TBRA) Financial Contrast|
www.americanbankingnews.com - September 7 at 12:06 AM
|Tobira Therapeutics (NASDAQ:TBRA) vs. Radius Health (RDUS) Head to Head Contrast|
www.americanbankingnews.com - July 15 at 6:20 PM
|The Lesson in Straight Path's Short Squeeze|
www.bloomberg.com - May 11 at 11:06 PM
|Biotech Forum Daily Digest: Upward Resistance Levels Continue To Hold; Spotlight On Foamix Pharmaceuticals|
seekingalpha.com - March 4 at 1:11 AM
|Allergan Hints It Is Ready to Make a Splash for More Near-term Growth|
us.rd.yahoo.com - January 11 at 5:38 AM
|Biotech Stocks on Investors' Radar -- Agenus, Portola Pharma, Tobira Therapeutics, and Auris Medical - PR Newswire (press release)|
www.prnewswire.com - November 1 at 12:21 PM
|TOBIRA THERAPEUTICS, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion of Acquisiti|
biz.yahoo.com - November 1 at 12:21 PM
|Notable Thursday Option Activity: TBRA, CRUS, BCOR - Nasdaq|
www.nasdaq.com - October 28 at 11:39 AM
|Notable Thursday Option Activity: TBRA, CRUS, BCOR|
www.nasdaq.com - October 27 at 7:46 PM
|Allergan CEO Brent Saunders Succeeds Paul Bisaro as Chairman|
www.wsj.com - October 26 at 7:37 PM
|Tobira Therapeutics (TBRA) Presents Phase 2b CENTAUR Year 1 Analysis at AASLD Annual Meeting|
www.streetinsider.com - October 20 at 7:55 PM
|Tobira Therapeutics Announces Late-Breaking Oral...|
www.benzinga.com - October 20 at 12:45 PM
|Allergan (AGN) Announces Early HSR Act Termination in Proposed Merger with Tobira|
www.streetinsider.com - October 19 at 7:13 PM
|FTC Grants Early Termination Of HSR Waiting Period For Allergan-Tobira Deal|
www.nasdaq.com - October 19 at 10:50 AM
|Controversy Over Allergan's 500% Premium for Tobira Looks Overdone|
www.thestreet.com - October 12 at 7:35 PM
Tobira Development (NASDAQ:TBRA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Tobira Development (NASDAQ:TBRA) Income Statement, Balance Sheet and Cash Flow Statement
Tobira Development (NASDAQ TBRA) Stock Chart for Thursday, February, 22, 2018